Literature DB >> 9373656

Comparison of 3, 5 and 7 days' treatment with Quinimax for falciparum malaria in Guinea-Bissau.

P E Kofoed1, E Mapaba, F Lopes, F Pussick, P Aaby, L Rombo.   

Abstract

For treatment of malaria, the World Health Organization recommends 10 mg of quinine per kg body-weight 3 times a day for at least 7 d. In Guinea-Bissau, as in several other African countries, a 3 d treatment regimen (10 mg/kg twice daily) is currently used. We therefore compared the 3 d treatment period with periods of 5 and 7 d. A total of 145 children with clinical malaria due to monoinfection with Plasmodium falciparum, with > or = 20 parasites per 200 leucocytes, were treated with intramuscular Quinimax 10 mg per kg body-weight twice daily for 3, 5 or 7 d. The children were then examined once weekly for 4 weeks. Following the 3 d treatment regimen, 34 of 43 children (79%) had parasitaemia on day 28 or before; following the 5 d treatment regimen, 36 of 40 children (90%) did so; and following the 7 d treatment regimen, 7 of 62 children (11%) were parasitaemic at that time. This study thus suggests that the currently recommended 3 d Quinimax treatment regimen in Guinea-Bissau for moderate and severe malaria is not effective.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Age Factors; Child; Demographic Factors; Developing Countries; Diseases; Drugs--therapeutic use; Guinea-bissau; Malaria; Parasitic Diseases; Population; Population Characteristics; Population Dynamics; Portuguese Speaking Africa; Research Report; Time Factors; Treatment; Western Africa; Youth

Mesh:

Substances:

Year:  1997        PMID: 9373656     DOI: 10.1016/s0035-9203(97)90286-8

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  6 in total

1.  Polymorphisms in Pfmdr1, Pfcrt, and Pfnhe1 genes are associated with reduced in vitro activities of quinine in Plasmodium falciparum isolates from western Kenya.

Authors:  Jelagat Cheruiyot; Luicer A Ingasia; Angela A Omondi; Dennis W Juma; Benjamin H Opot; Joseph M Ndegwa; Joan Mativo; Agnes C Cheruiyot; Redemptah Yeda; Charles Okudo; Peninah Muiruri; Ngalah S Bidii; Lorna J Chebon; Paul O Angienda; Fredrick L Eyase; Jacob D Johnson; Wallace D Bulimo; Ben Andagalu; Hoseah M Akala; Edwin Kamau
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 2.  Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria.

Authors:  Jane Achan; Ambrose O Talisuna; Annette Erhart; Adoke Yeka; James K Tibenderana; Frederick N Baliraine; Philip J Rosenthal; Umberto D'Alessandro
Journal:  Malar J       Date:  2011-05-24       Impact factor: 2.979

3.  Malaria transmission in Bissau, Guinea-Bissau between 1995 and 2012: malaria resurgence did not negatively affect mortality.

Authors:  Johan Ursing; Lars Rombo; Amabelia Rodrigues; Peter Aaby; Poul-Erik Kofoed
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

4.  Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau - An Open-Label Non-Inferiority Randomised Clinical Trial.

Authors:  Johan Ursing; Lars Rombo; Amabelia Rodrigues; Poul-Erik Kofoed
Journal:  PLoS One       Date:  2016-09-20       Impact factor: 3.240

5.  Dynamic changes in genetic diversity, drug resistance mutations, and treatment outcomes of falciparum malaria from the low-transmission to the pre-elimination phase on the islands of São Tomé and Príncipe.

Authors:  Ying-An Chen; Tsen-Ju Shiu; Lien-Fen Tseng; Chien-Fu Cheng; Wei-Liang Shih; Arlindo Vicente de Assunção Carvalho; Kun-Hsien Tsai
Journal:  Malar J       Date:  2021-12-14       Impact factor: 2.979

6.  Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial.

Authors:  Jane Achan; James K Tibenderana; Daniel Kyabayinze; Fred Wabwire Mangen; Moses R Kamya; Grant Dorsey; Umberto D'Alessandro; Philip J Rosenthal; Ambrose O Talisuna
Journal:  BMJ       Date:  2009-07-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.